Bone Biologics (BBLG) Amortization of Deferred Charges (2015 - 2018)
Bone Biologics (BBLG) posted quarterly Amortization of Deferred Charges of $1694.0 for Q3 2018, down 82.71% year-over-year from $9795.0 in Q3 2017, and down 82.71% quarter-over-quarter from $9795.0 in Q2 2018.
Powered by 
Analysis
Bone Biologics (BBLG) Amortization of Deferred Charges (2015 - 2018) Analysis & Trends
Bone Biologics (BBLG) has reported Amortization of Deferred Charges for 4 consecutive years, with $1694.0 the latest figure, recorded in Q3 2018.
- In Q3 2018, Amortization of Deferred Charges fell 82.71% year-over-year to $1694.0; the TTM figure through Dec 2019 stood at $1694.0 (down 92.04% YoY), while the FY2018 annual figure was $21283.0, down 45.67% from the prior year.
- Amortization of Deferred Charges declined to $1694.0 in Q3 2018 per BBLG's latest filing, from $9795.0 in the prior quarter.
- Across five years, Amortization of Deferred Charges topped out at $414917.0 in Q1 2015 and bottomed at $1694.0 in Q3 2018.
- Historically, Amortization of Deferred Charges has averaged $51804.9 across 4 years, with a median of $9795.0 in 2017.
- Annual changes were most pronounced in 2016 — Amortization of Deferred Charges plunged 93.83% — and 2017, when it rose 0.02%.
- Bone Biologics' Amortization of Deferred Charges stood at $61836.0 in 2015, then plunged by 84.16% to $9796.0 in 2016, then fell by 0.02% to $9794.0 in 2017, then sank by 82.7% to $1694.0 in 2018.
- Business Quant data shows BBLG's Amortization of Deferred Charges at $1694.0 in Q3 2018, $9795.0 in Q2 2018, and $9794.0 in Q1 2018.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 141.52 Bn | 133.66 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.69 Bn | 78.69 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.63 Bn | 59.45 Bn | 1.37 Bn |
| 4 | Moderna | 59.30 Bn | 54.16 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.41 Bn | 44.41 Bn | - |
| 6 | BeOne Medicines | 40.45 Bn | 35.35 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.29 Bn | 31.98 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - |
| 9 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn |
| 10 | Bone Biologics | 1.00 Mn | 1.00 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2018 | 1,694.00 |
| Jun 30, 2018 | 9,795.00 |
| Mar 31, 2018 | 9,794.00 |
| Dec 31, 2017 | 9,794.00 |
| Sep 30, 2017 | 9,795.00 |
| Jun 30, 2017 | 9,794.00 |
| Mar 31, 2017 | 9,794.00 |
| Dec 31, 2016 | 9,796.00 |
| Sep 30, 2016 | 9,793.00 |
| Jun 30, 2016 | 9,794.00 |
| Mar 31, 2016 | 25,613.00 |
| Dec 31, 2015 | 61,836.00 |
| Sep 30, 2015 | 61,837.00 |
| Jun 30, 2015 | 123,027.00 |
| Mar 31, 2015 | 414,917.00 |